Andrew Brunner

In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.

Doctors David Sallman and Andrew Brunner discuss updates in myelodysplastic syndromes at ASH 2022. Topics include treatment options for lower-risk and higher-risk disease, trial updates, novel classification systems, and therapies after failure to hypomethylating agents.